VivoSeq
Other

T-ALL

1

Pipeline Programs↗

8

Active Trials↗

2

Companies Involved↗

T-ALL is an early-stage landscape with 1 program across 2 companies. The most active players are Roche, BIOHENG THERAPEUTICS US LLC.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

15/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

0 programs

PreclinicalB

BIOHENG THERAPEUTICS US LLC

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Isatuximab

Azienda U.S.L. 1 di Massa e Carrara

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

13

clinical trials

Recruiting6 · 46%
Completed4 · 31%
Not yet recruiting2 · 15%
Unknown status1 · 8%

Clinical Trials

Trial Activity

13 trials

Venetoclax and Decitabine in R/R T-ALL
Recruiting·SSeoul National University Hospital·Phase 2·NCT06712121·28 enrolled
U69-CART-Cells For R/R T-ALL
Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT07350863·12 enrolled
VHAG in Treating R/R T-ALL/LBL
Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06742463·50 enrolled
Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients
Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT06381817·146 enrolled
A Study of CTD402 in T-ALL/LBL Patients
Recruiting·BBIOHENG THERAPEUTICS US LLC·Phase 1/2·NCT07070219·54 enrolled
A Multicenter, Single-arm Phase II Study to Assess the Safety, Tolerability, and Efficacy of Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia (GMALL-Isatuximab)
Recruiting·GGoethe University·Phase 2·NCT06648889·40 enrolled
BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT06673459·430 enrolled
Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants
Not yet recruiting·NN-Fold, LLC·Phase 1/2·NCT07117669·68 enrolled
Venetoclax Based Regimen for R/R T-ALL
Completed·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05149378·25 enrolled
Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen?
Completed·HHamilton Health Sciences Corporation·Phase 4·NCT00716963·7 enrolled
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
Completed·Roche logoRoche·Phase 2·NCT00382148·10 enrolled
CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL
Completed·—·Phase 1·NCT05716113·20 enrolled
RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL
Unknown status·—·N/A·NCT04620655·24 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)